ARAdam H. Ross

Adam H. Ross

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Adam H. Ross has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Recommendations by a UK expert panel on an aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration

    by Adam H. Ross, Louise Downey, Helen Devonport, Richard P. Gale, Ajay Kotagiri, Sajjad Mahmood, Hemal Mehta, Niro Narendran, Praveen J. Patel, Nina Parmar, et al.

    Objectives: This report aims to provide clear recommendations and practical guidance from a panel of UK retinal experts on an aflibercept treat-and-extend (T&E) pathway that can be implemented in clinical practice. These recommendations may help service providers across the NHS intending to implement a T&E approach, with the aim of effectively addressing the capacity and resource issues putting strain on UK neovascular age-related macular degeneration (nAMD) services while promoting patients’ best interests throughout. Methods: Two structured roundtable meetings of retinal specialists were held in London, UK on 7 December 2018 and 1 March 2019. These meetings were organised and funded by Bayer. Results: The panel provided recommendations for an aflibercept T&E pathway and developed specific criteria based on visual acuity, retinal morphology and optical coherence tomography imaging to guide reduction, maintenance and extension of injection intervals. They also discussed the extension of treatment intervals by 2- or 4-week adjustments to a maximum treatment interval of 16 weeks, the management of retinal fluid and the stopping of treatment. Conclusions: The long-term benefits of implementing a T&E pathway may include superior visual outcomes compared with a pro re nata (PRN; as needed) protocol, and a lower treatment burden compared with a fixed protocol, which is likely to improve service capacity. Furthermore, the predictable nature of a T&E approach compared with a PRN service may aid capacity planning for the future nAMD treatment demand.


  • Open Access

    The management of diabetic macular oedema

    by Adam H. Ross, C. Clare Bailey

    Diabetic macular oedema (DMO) is a significant cause of visual loss in the working population. Focal/grid photocoagulation remains an effective treatment for DMO and the benchmark to which clinicians compare other newer treatment modalities. There are, however, patients who do not respond adequately or who are refractory to laser photocoagulation. This has led to the development of newer treatments such as the intravitreal injection of vascular endothelial growth factor (VEGF) inhibitors as well as intravitreal corticosteroid releasing delivery systems. Cataract formation and raised intraocular pressure remain the major disadvantages of corticosteroid use. There is mounting evidence that intravitreal VEGF inhibitors with or without combined laser photocoagulation will become the gold standard treatment for DMO.


  • The Use of Imiquimod in the Treatment of Periocular Tumours

    by A. H. Ross, C. T. C. Kennedy, C. Collins, R. A. Harrad

    Purpose: To review our experience with 5% topical Imiquimod in the treatment of periocular tumours. Methods: Imiquimod, an imidazoquinoline, is an immune response modifier which has been shown to have potent anti-viral and anti-tumour activity. We present a retrospective case series of 5 patients who received topical Imiquimod for various eyelid tumours. Two patients were diagnosed with basal cell carcinoma of the eyelid, one patient with actinic keratosis, one with intraepidermal squamous cell carcinoma (Bowen’s disease) and one patient had concomitant squamous cell carcinoma and intraepidermal squamous cell carcinoma. Results: All 5 patients, with various eyelid neoplastic/pre-neoplastic pathology, responded well with clinical resolution, to treatment with topical Imiquimod. There were few adverse reactions to periocular use of 5% Imiquimod, with only 1 patient developing a chemical conjunctivitis which resolved on dose reduction. Conclusions: There is limited experience and published literature on the use of topical 5% Imiquimod in the treatment of periocular tumours. In our experience, it is a safe and effective treatment for periocular lesions, including actinic keratosis, intraepidermal squamous cell carcinoma, basal cell carcinoma and squamous cell carcinoma. To our knowledge, this is the first published description of the successful use of 5% Imiquimod in treating moderately differentiated squamous cell carcinoma of the eyelid.


  • Long-term Topical Steroid Treatment after Penetrating Keratoplasty in Patients with Pseudophakic Bullous Keratopathy

    by Adam H Ross, Mark N A Jones, Dan Q Nguyen, Philip D Jaycock, W John Armitage, Stuart D Cook, Stephen B Kaye, Derek M Tole, National Health Service Blood and Transplant Ocular Tissue Advisory Group and Contributing Ophthalmologists


  • The use of rituximab in refractory mucous membrane pemphigoid with severe ocular involvement

    by A H Ross, P Jaycock, S D Cook, A D Dick, D M Tole

    A 37-year-old gentleman presented to our clinic with a 3-month history of sore red eyes, treated with topical chloramphenicol for presumed bacterial conjunctivitis. During the preceding 3 months, he reported mouth and penile ulcers, dysphagia, hoarseness and blistering of plantar aspect of his right foot. Examination revealed …